Luque-Ramírez, Manuel
Ortiz-Flores, Andrés E.
Nattero-Chávez, Lía
Martínez-García, M.Ángeles
Insenser, María
Álvarez-Blasco, Francisco
Fernández-Durán, Elena
Quintero-Tobar, Alejandra
de Lope Quiñones, Sara
Escobar-Morreale, Héctor F.
Funding for this research was provided by:
Instituto de Salud Carlos III (PI1400649, PI1501686 and PIE1600050, PI1400649, PI1501686 and PIE1600050, PI1400649, PI1501686 and PIE1600050, PI1400649, PI1501686 and PIE1600050, PI1400649, PI1501686 and PIE1600050, PI1400649, PI1501686 and PIE1600050, PI1400649, PI1501686 and PIE1600050, PI1400649, PI1501686 and PIE1600050, PI1400649, PI1501686 and PIE1600050, PI1400649, PI1501686 and PIE1600050)
Article History
Received: 15 June 2021
Accepted: 29 October 2021
First Online: 11 November 2021
Competing interests
: M.L.-R. has received consulting fees and honoraria for speaking from Novo Nordisk and Merck, and was involved in clinical trials supported by AstraZeneca, Cortendo AB, and Neurocrine. A.E. O.-F. was involved in a clinical trial supported by Cortendo AB. L.N.-C- has received consulting fees and honoraria for speaking from Novo Nordisk and Sanofi Aventis, and was involved in clinical trials supported by AstraZeneca, Cortendo AB, Diamyd Medical, and Neurocrine. F. A.-B. has received consulting fees and honoraria for speaking from Novo Nordisk, AstraZeneca, Menarini, and Lilly-Boehringer, and was involved in clinical trials supported by AstraZeneca and Diamyd Medical. E.F-D and A.Q.-T. were involved in clinical trials supported by AstraZeneca, Cortendo AB, Diamyd Medical, and Neurocrine. H.F. E.-M. was involved in a clinical trial supported by AstraZeneca, and has received consulting fees from InsudPharma. All other authors have no conflict of interest.